1. Proposal Title *

2. Applicant information *

Applicant name, affiliation and contact details.

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Postal Code</th>
<th>Email</th>
<th>Phone</th>
<th>Fax</th>
</tr>
</thead>
</table>

3. Brief abstract of proposal and supporting rationale. (Limited 500 words) *

4. Please indicate key milestones, time line and go/no-go decisions. (Limited 500 words) *

5. Brief summary of prior research and clinical trials conducted by the applicant, including titles and references to relevant publication (Limited 500 words) *

6. Key collaborators / co-investigators including name, affiliation and contact details. *

Collaborator #1

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Address</th>
<th>City</th>
<th>State</th>
<th>Postal Code</th>
<th>Email</th>
<th>Phone</th>
<th>Fax</th>
</tr>
</thead>
</table>

7. Has a funding body requested the review of the drug / technology? *

- Yes - No

If yes, please provide details

8. List specific guidance and questions requested from TACT. *

9. Scientific rationale *

The following sections should include references and take into account other known data in the field. Please include unpublished data as well as published data. Please attach a Gantt chart or a time line of planned preclinical activities.

9.a Target validation. How is the biological target associated with the disease? How has this been demonstrated? (Limited 300 words)

9.b Preclinical data available (see http://www.treat-nmd.eu/resources/tact/guidance/): please provide specific data results relevant to this application

9.b.I Indicate the model used for preclinical proof of concept. Is it a standard model, and for DMD does the model follow the recent guidelines for Standard Operating Procedures? (http://www.treat-nmd.eu/research/preclinical/SOPs/) Please provide references. (Limited 300 words)

9.b.II Comment on the predictivity of the model in relation to the intended research. (Limited 250 words) Please note: this information is in addition to that provided above.

9.b.III Provide critical assessment of animal data taking into consideration data generated by independent laboratories with the model. (Limited 250 words) Please note: this information is in addition to that provided above.

9.c Is there a reliable assay for drug activity?

Biomarker:
9.d Any biomarkers employed?  
| Yes | No |

If yes, how do they relate to subsequent clinical trials?

9.e If no preclinical work conducted yet, what is being proposed including plans and timelines for completion of studies?

9.f Critical assessment - list limitations of the proposed research. (Limited 500 words)

10. Drug License *

10.a Is the drug currently licensed?  
| Yes | No |

10.a.I If yes, what are the current indications for use of this drug?

10.a.II If yes, where was the drug licensed for use and in which age group?

10.b Is there clinical experience in any other indication?  
| Yes | No |

If yes, please describe:

10.c Is there prior human experience with the study drug in the proposed indication? Provide data from other trials. Highlight what differentiates your proposal from other planned, ongoing or completed trial(s).

10.d If the drug was not licensed, is there prior human experience? Describe and provide available references.

11. Toxicology / Safety Assessment *

11.a Has a Toxicology / Safety Assessment been performed?  
| Yes | No |

11.b If yes, indicate below data available.  
11.b.I No adverse effect levels (NOAEL)  
| Yes | No |

11.b.II Maximum tolerated dose (MTD)  
| Yes | No |

11.b.III Multiple dose safety  
| Yes | No |

11.b.IV Gene toxicology  
| Yes | No |

11.b.V Cardiovascular  
| Yes | No |

11.b.VI Reproductive Toxicology  
| Yes | No |

11.b.VII CNS safety  
| Yes | No |

11.b.VIII Off-target pharmacology  
| Yes | No |

11.c What are the expected side effects in patients (for drugs with prior clinical data)?

11.d Other studies
12. Absorption, Distribution, Metabolism and Excretion (ADME)

12.a Pharmacokinetics (PK) in multiple species. 
- Yes ✗ No

12.b In vitro ADME (metabolism, protein binding, permeability) 
- Yes ✗ No

12.c Biodistribution study 
- Yes ✗ No

13. Have assays been developed for regulatory filing: e.g. PK, immunogenicity as applicable? * 
- Yes ✗ No
If yes, please provide details:

14. Chemistry-Detail physical characteristics of compound

14.a Melting point, crystallinity

14.b Solubility

15. Clinical Protocol: Attach study synopsis or protocol if available and investigator brochure if available. *

15.a What are the trial objectives? Please provide primary and secondary endpoints.

15.b If the applicant is not the clinician conducting the trial please provide name of clinician who will be the principal investigator, and include prior relevant clinical trial experience.

15.c Describe the statistical design:
15.c.I Sample size and rationale.

15.c.II Are the endpoints sensitive to change? (prior data to support)

15.c.III Number of subjects per treatment group.

15.c.IV Effect size expected and is it expected to be clinically meaningful? (how is this measured?)

15.c.V Intent to treat? Handling of lost to follow-up and missing data.

15.c.VI Is there a plan for interim analysis? If adaptive design, plan for adaptation without breaking blind?

15.d Will participants receive standard care? (e.g. discuss use of corticosteroids if applicable)

15.e Patient inclusion and exclusion criteria. Explain choice of patient population and rationale for eligibility criteria.

15.f Rationale for dose selection?

15.g Rationale for formulation? Route?

15.h Rationale for duration of treatment?

15.i Plans for blinding and for avoiding bias in evaluation?

15.j Describe the study schedule and length of visits.

15.k Endpoints
15.k.I Have the study endpoints been used in prior trials and for regulatory approval for this or other indications?

15.k.II Do the endpoints of the study support later phase studies / approval? Explain.
15.k.III Have endpoints been validated in the population (age range)? Summarize existing data. (Limited 150 words)

15.k.IV Comment on reliability and monitoring of endpoints/outcomes measurements.

15.k.V Plans for study personnel training for endpoint measurement.

15.k.VI If the primary outcome is not clinical is it an established biomarker?

15.l If proposed study intervention is not effective, what will be learned from study?

15.m Will trial test biological mechanism, i.e. will it address if other drugs targeting the same mechanism should be pursued? Will it include a pharmacodynamic marker?

15.n Safety considerations - indicate below unless included in protocol and IB.
15.n.I Any expected class effects, off target effects, QTc prolongation-hERG, genotoxicity, teragenicity, fetal effect issues?

15.n.II Any other red flags?

15.n.III Drug interactions? How is the drug cleared?

15.n.IV Any renal or liver impairment clearance issues etc? Please provide details.

15.n.V Describe the safety monitoring plan that has been developed.

15.n.VI Will an independent blinded safety reviewer or a data safety monitoring board (DSMB) be used?

16. Clinical study conduct *

16.a How many sites will be involved in the trial and have they already been identified?

16.b Include number of patients per site meeting eligibility criteria?

16.c What are the enrollment projections and what are they based on?

16.d Have other trials in the same population been considered in the projections? Please specify.

16.e Do study design and logistics take into consideration prior relevant clinical studies in the patient population?

16.f Implementation: is a clinical trial network established for the disease? Can existing networks be used? Qualified investigators/evaluators available at sufficient number of sites?

16.g Will proposed project help establish a network that can potentially support future research studies?

16.h Have you contacted the TREAT-NMD Clinical Trial Facility (CTCC)?

17. Regulatory *

17.a Has there been any past interaction with a regulatory agency or is there any interaction planned?

17.b Has your product been designated as an orphan drug in EU and/or USA?
If not, do you intend to submit a dossier?

18. Study drug considerations *

18.a Can formulated drug be manufactured according to requirements for human testing?
- Yes  
- No

18.b Can the study drug be produced routinely?
- Yes  
- No

18.c Is the cost of the study drug(s) considered in the budget?
- Yes  
- No

Please provide details

18.d Is there a GMP process available?
- Yes  
- No

18.e Yield of current process?

18.f Has the process been optimized and scaled up?
- Yes  
- No

18.g What is the largest scale to date?

18.h Who will supply and has supply been secured for this trial?

18.i If data supports continuation of program is material supply available for subsequent trials?
- Yes  
- No

18.j Who will manufacture study drug (and comparator, if applicable)? Please specify extent of commitment.

19. Has the IP status been considered? *

19.a Have you filed for patent and composition of matter, or method claims?
- Yes  
- No

19.b If so, what is the length of the patent?

19.c Have you published without filing for patent?
- Yes  
- No

19.d Do others have license to use technology/compound?
- Yes  
- No

If yes, who?

19.e Do you have complete freedom to operate?
- Yes  
- No

20. Funding and resources *

20.a Anticipated cost of proposal; include per patient cost, infrastructure cost, other.

20.b Any expressed interest for funding project?
- Yes  
- No

If yes, please give details

20.c Is the study fundable beyond this project?
- Yes  
- No

If yes, please give details

20.d Potential funders?
- Yes  
- No

If yes, please give details

20.e Have any resources been identified to support the proposal?
- Yes  
- No

If yes, please give details
21. Who would be interested to potentially continue the program after phase I/II-POC, pursue registration if data support?

22. How do you plan to use the TACT report (tick all that apply)?

22.a Apply for funding  
- Yes  
- No

22.b Discussion / liaison with regulatory agencies (FDA, EMA, etc)  
- Yes  
- No

22.c Planning / prioritising work  
- Yes  
- No

22.d Other  
- Yes  
- No

If other, please specify...